MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3)

Houston, Texas 77030

0 studies enrolling now · 7 studies all time

What they study most

Hematologic Malignancies, PI3K Pathway Activated Tumors, PTCH1 or SMO Activated Solid and Hematologic Tumors, Solid Tumor, Solid Tumor and Hematologic Malignancies, Tumor Pathway Activations Inhibited by Dovitinib, Tumors With Aberrations in ALK or ROS1, Tumors With CDK4/6 Pathway Activation

Studies at this site

• Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) — Stopped early
• MEK162 for Patients With RAS/RAF/MEK Activated Tumors — Completed
• LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) — Completed
• BGJ398 for Patients With Tumors With FGFR Genetic Alterations — Stopped early
• BKM120 for Patients With PI3K-activated Tumors — Completed
• Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib — Completed
• LDE225 for Patients With PTCH1 or SMO Mutated Tumors — Stopped early